Forest Laboratories ($FRX) posted a drop in fiscal second-quarter earnings on higher costs, but sales rose 9%, thanks to strong early sales of two new products. But revenue still depends heavily on two older products, Lexapro and Namenda, that are on the verge of losing patent protection, and analysts wonder whether Forest's new drugs are novel enough to capture sizable market share. Report | News